Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Effect of FcγRIIIA Gene Polymorphism on the Treatment of Diffuse Large B-cell Non-Hodgkin Lymphoma: A Multicenter Prospective Observational Study.

Turkish journal of haematology : official journal of Turkish Society of Haematology - 1 Jun 2015

Büyükkurt Nurhilal, Özcan Mehmet Ali, Ergene Ülkü, Payzın Bahriye, Tunalı Sunay, Demirkan Fatih, Özsan Hayri, Pişkin Özden, Ündar Bülent

Abstract excerpt

OBJECTIVE: The curative treatment approach for diffuse large B-cell lymphoma (DLBCL) is controversial even in the rituximab (R) era. The aim of this study was to examine the FcγRIIIA gene polymorphism distribution of DLBCL patients who had been treated with R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. Furthermore, we investigated the impact of FcγRIIIA gene polymorphism on the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclophosphamide
Share to Doxorubicin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphoma, Large B-Cell, Diffuse

Share to Prednisone

Share to Receptors, IgG

Share to Rituximab

Share to Turkey

Share to Vincristine

Source

Open in PubMed Open full text

Identifiers

PMID: 26316483
DOI: 10.4274/tjh.2013.0367
PMCID: PMC4451483

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Effect of FcγRIIIA Gene Polymorphism on the Treatment of Diffuse Large B-cell Non-Hodgkin Lymphoma: A Multicenter Prospective Observational Study.PMID 26316483Read ↗

Correlation of FcγRIIIa Polymorphisms to the Response of Rituximab in Thai Patients with Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.Semantic proximity Read ↗

FCGR3A polymorphism : It is helpful for the management of diffuse large B-cell lymphomaSemantic proximity Read ↗

[Efficacy of rituximab therapy on diffuse large B-cell lymphoma with different Fcgamma RIIIA gene polymorphisms: a prospective study].Semantic proximity Read ↗

Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol.Semantic proximity Read ↗

Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma.Semantic proximity Read ↗

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.Semantic proximity Read ↗

FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients.Semantic proximity Read ↗

The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab.Semantic proximity Read ↗

FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma.Semantic proximity Read ↗

The H/R FcγRIIA-131 polymorphism and survival in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP: a study in a genetically mixed population.Semantic proximity Read ↗

FcγRIIa-H131R variant is associated with inferior response in diffuse large B cell lymphoma: A meta-analysis of genetic risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.